Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score

Río, Jordi; Rovira, Àlex; Blanco, Yolanda; Sainz, Albert; Perkal, Héctor; Robles, René; Ramió-Torrentà, Ll; Díaz, Rosa M; Arroyo, Rafael; Urbaneja, Patricia; Fernández, Óscar; García Merino, José A; Reyes, María del Pino; Oreja Guevara, Celia; Prieto, José M; Izquierdo, Guillermo; Olascoaga, Javier; Álvarez Cermeño, José C; Simón, Eva; Pujal, Berta; Comabella, Manuel; Montalban, Xavier.
Rev. neurol. (Ed. impr.) ; 63(4): 145-150, 16 ago., 2016. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-155474

Documentos relacionados

  1. Dealing With Treatment-Confounder Feedback and Sparse Follow-up in Longitudinal Studies: Application of a Marginal Structural Model in a Multiple Sclerosis Cohort.
  2. Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-ß therapy of multiple sclerosis patients.
  3. [Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score].
  4. Comorbidity patterns in people with multiple sclerosis: A latent class analysis of the Australian Multiple Sclerosis Longitudinal Study.
  5. Modelling Disease Progression of Multiple Sclerosis in a South Wales Cohort.
  6. Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
  7. Association of obesity with disease outcome in multiple sclerosis.
  8. Is the sharp increasing trend of multiple sclerosis incidence real in Iran?
  9. Clinical characteristics and dynamics of disability progression in a cohort of patients with multiple sclerosis in Latvians.
  10. Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data.